ESC 2013: Medtronic's Symplicity hypertension treatment still promising at 1 and 3 years

September 3, 2013 by Ingrid Mezo

A pair of Medtronic studies support the Symplicity renal denervation system in treatment of patients with drug-resistant hypertension, with promising results at 1 and 3 years following treatment.

ESC 2013: Medtronic renal denervation going strong at 3 years

New data on Medtronic's (NYSE:MDT) Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.